Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 9/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10423399 | 0.85 | MEN1 (0.56) | MEN1TP53PABPC1KMT2ACXCR3 | |
| SCHEMBL9850780 | 0.84 | EGLN3 (0.63) | MEN1TP53PABPC1KMT2AEGLN3 | |
| SCHEMBL2194087 | 0.81 | KMT2A (0.52) | MEN1TP53PABPC1KMT2AEGLN3 | |
| SCHEMBL16879622 | 0.80 | MEN1 (0.50) | MEN1TP53PABPC1KMT2ACXCR3 | |
| SCHEMBL15491688 | 0.79 | TP53 (0.50) | MEN1TP53PABPC1KMT2ACXCR3 | |
| SCHEMBL15484962 | 0.79 | LMNA (0.51) | MEN1TP53PABPC1KMT2A | |
| SCHEMBL2220958 | 0.79 | KMT2A (0.50) | MEN1TP53PABPC1KMT2ACXCR3 | |
| SCHEMBL3588649 | 0.79 | TP53 (0.53) | MEN1TP53PABPC1KMT2ACXCR3 | |
| SCHEMBL2222060 | 0.76 | TP53 (0.47) | MEN1TP53PABPC1KMT2ACXCR3 | |
| SCHEMBL1035783 | 0.76 | EGLN3 (0.71) | PTGS2EGLN3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-3245203-B1 | HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-14 | — | — | EP | disclosed |
| US-10053457-B2 | Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2018-08-21 | — | — | US | disclosed |
| EP-3122741-B1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-06-06 | — | — | EP | disclosed |
| US-9951063-B2 | 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-24 | — | — | US | disclosed |
| EP-2888261-B1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20180009799-A1 | HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-11 | — | — | US | disclosed |
| EP-3245203-A1 | HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2017-11-22 | — | — | EP | disclosed |
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| EP-2809668-B1 | 4-(BENZOIMIDAZOL-2-YL)-THIAZOLE COMPOUNDS AND RELATED AZA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-01-29 | — | — | US | disclosed |
| CN-101115764-A | New macrolides | BASILEA PHARMACEUTICA AG (CH) | 2008-01-30 | — | — | CN | disclosed |
| WO-2007100610-A2 | PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007070433-A2 | 2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053457-B2 | Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators | CXCR3, CXCR1, CXCR2 | MEN1 4604/4885TP53 2340/4885PABPC1 4832/4885 |
| US-20170107214-A1 | 8-(PIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-ISOQUINOLINE DERIVATIVES | CXCR3, CXCR1, CXCR2 | MEN1 3348/4885TP53 1748/4885PABPC1 4695/4885 |
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | MEN1 4760/4885TP53 3706/4885PABPC1 1582/4885 |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CX3CR1 | MEN1 4040/4885TP53 2065/4885PABPC1 3837/4885 |
| US-20180009799-A1 | HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | CXCR3, CXCR1, CXCR2 | MEN1 4604/4885TP53 2340/4885PABPC1 4832/4885 |
| US-20090030012-A1 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators | CXCR3, CXCR1, CXCR5 | MEN1 4812/4885TP53 1065/4885PABPC1 2808/4885 |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | MEN1 4848/4885TP53 2604/4885PABPC1 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.